Entrada Therapeutics (TRDA) 10% Owner MPM BioVentures Sells Shares

What Happened

• MPM BioVentures (a reported 10% owner of Entrada Therapeutics, ticker TRDA) sold a total of 86,482 shares in open-market transactions across Sept 1–3, 2026. The sales were: 29,088 shares on 2026-09-01 for $205,361 (avg $7.06), 25,131 shares on 2026-09-02 for $180,692 (avg $7.19), and 32,263 shares on 2026-09-03 for $231,326 (avg $7.17). Aggregate proceeds were about $617,379 and the combined weighted-average price was roughly $7.14 per share. These were sales (S), not purchases.

Key Details

• Transaction dates and values:
  • 2026-09-01: 29,088 shares @ $7.06 — $205,361
  • 2026-09-02: 25,131 shares @ $7.19 — $180,692
  • 2026-09-03: 32,263 shares @ $7.17 — $231,326
• Total sold: 86,482 shares for ~$617,379 (weighted avg ≈ $7.14/share).
• Holdings after the transactions: related MPM funds still collectively hold roughly 4.1 million shares across the listed vehicles (see footnotes for per-fund breakdown).
• Footnotes: sales were allocated among several related funds (BV 2014, BV 2018 and affiliated entities); managing directors Evnin, Foley and Gadicke are named as managers of the GP/manager entities. The filing includes weighted-average sale prices and price ranges in footnotes; see the Form 4 for full per-price details.
• Filing timeliness: Form 4 was filed 2026-09-03 reporting transactions from Sept 1–3; no late-filing flag is indicated.

Context

• This is institutional selling by a reported 10% owner (multiple related MPM funds). Institutional sales are common for portfolio management or liquidity reasons and do not necessarily reflect insider views about company fundamentals. No options exercise, gift, or purchase was reported — these were open-market sales (code S). For precise per-entity holdings and the allocation of shares sold across the related funds, refer to the footnotes and the full Form 4.